+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Prenatal Diagnostic Testing

  • ID: 3068114
  • Report
  • Region: Global
  • 107 Pages
  • Insight Pharma Reports
1 of 3

FEATURED COMPANIES

  • Ariosa Diagnostics
  • Metabolomic Diagnostics
  • Natera
  • NX PharmaGen
  • Sequenom
  • Silicon Biosystems
  • MORE
This report discusses improvements in invasive procedures (karyotyping vs. cytogenetics), and the rise of noninvasive screening methods and their impact on prenatal healthcare. Although covering standard invasive procedure, this report focuses on the noninvasive technologies either on the market or in development.

The first chapter of this report discusses microarray-based cytogenetics and how it compares to karyotyping. Karyotyping is often the standard method used to detect chromosomal aneuploidies, but with microarray-based procedures even more aneuploidies can be detected with the same efficacy. Either method can be used in sync with noninvasive procedures that show positive screening results for aneuploidies, but microarray analysis may be more useful for copy number variations that often go undetected with karyotyping.

Highlighting noninvasive methods, several companies have come out with novel technologies that allow them to analyze fetal DNA without risk of injury to the mother or fetus. Amniocentesis and chorionic villus sampling are common methods used to analyze fetal DNA for aneuploidies but at the risk of miscarriage and infection. With noninvasive procedures, screening can be done for common aneuploidies and further analysis can be done on women with only positive results. This not only decreases the amount of unnecessary invasive testing but also the amount of unnecessary stress levels of many expecting mothers. Companies participating in this section include:

- Sequenom
- Verinata Health
- Ariosa Diagnostics
- Natera
- Silicon Biosystems

Other areas discussed in this report include preeclampsia and preterm labor. Preeclampsia is a common condition in women and often isn’t detected until later in pregnancy. It can lead to preterm labor, which may be fatal for both the fetus and the mother. So far, a test to screen for the likelihood of preeclampsia does not exist. Detecting the risk of preeclampsia early in pregnancy can allow the expecting mother to take necessary action to avoid preterm labor at all costs, decreasing any complications that may severely affect the fetus including death.

Companies highlighted in this section include:

- Metabolomic Diagnostics
- NX PharmaGen

In addition to covering several aspects of prenatal diagnostics, this report also includes specifications of particular instruments, exclusive interviews with CEOs, CSOs, and Vice Presidents of the participating companies. Specific areas of focus include company goals, customer feedback, challenges encountered, competitive advantage, platform pricing, and future endeavors. A survey capturing the demographics of the prenatal industry is presented at the end of the report, specifically highlighting organizational background, areas of research, challenges encountered, and applications in development.

Also included is a directory of companies that were and were not interviewed for this report.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Ariosa Diagnostics
  • Metabolomic Diagnostics
  • Natera
  • NX PharmaGen
  • Sequenom
  • Silicon Biosystems
  • MORE
Executive Summary

Part I: Prenatal Applications

CHAPTER 1: Invasive Testing

Karyotyping

Microarray analysis

CHAPTER 2: Noninvasive Testing

Sequence-based cell-free DNA testing

Fetal cell isolation

Part II: Noninvasive Prenatal Applications

CHAPTER 3: Sequenom

Company background

Areas of Research

MaterniT21™ PLUS

MaterniT21 PLUS validation

Competitive advantage

Future endeavors

Interview with William Welch; Dirk van den Boom; and Allan Bombard

- Company background
- Technologies in development
- SEQureDx platform
- MaterniT21 platform
- Validation techniques
- Areas of improvement
- Competitive advantage
- Customer feedback
- Future endeavors

CHAPTER 4: Verinata Health

Company background

The verifi® prenatal test

Challenges encountered

Clinical validation and reimbursement

Customer feedback

Interview with Richard Rava

- Company background
- verifi® prenatal test
- Challenges encountered
- Competitive advantage

CHAPTER 5: Ariosa Diagnostics

Company background

Harmony Prenatal Test

Competitive advantage

Future endeavors

Interview with Tom Musci

- Company background
- Harmony Test
- Competitive advantage
- Future endeavors

CHAPTER 6: Natera

Company background

Panorama

Platform improvements

Validation

Challenges encountered

Competitive advantage

Future endeavors

Interview with Solomon Moshkevich

- Company background
- Panorama
- Platform improvements
- Validation
- Challenges encountered
- Customer feedback
- Competitive advantage
- Future endeavors

CHAPTER 7: Silicon Biosystems

Company background

DEPArray System

Challenges encountered

Competitive advantage

Future endeavors

Interview with Robert Proulx

- Company background
- DEPArray Platform
- Challenges encountered
- Customer feedback
- Future endeavors

CHAPTER 8: Noninvasive Screening Test Specifications

Part III: Prenatal Complications

CHAPTER 9: Prenatal Complications

Preeclampsia

Preterm labor

CHAPTER 10: Metabolomic Diagnostics

Company background

Preeclampsia screening test

Competitive advantage

Future endeavors

Interview with Charles Garvey

- Company background
- Areas of research
- Competitive advantage
- Future endeavors

CHAPTER 11: NX PharmaGen

Company background

NeXosome platform

Competitive advantage

Future endeavors

Interview questions with Dr. Alan Ezrin and Brian Brohman

- Company background
- Preterm labor assays
- Challenges encountered
- Competitive advantage
- Future endeavors

Part IV: Demographic Survey

CHAPTER 12: Survey Results

Survey demographics

Areas of research

Challenges encountered

Applications being used for prenatal diagnostics

Competitive strategies

Part V: Company Directory: A list of companies working in Prenatal Diagnostics

References
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
- Ariosa Diagnostics
- Metabolomic Diagnostics
- NX PharmaGen
- Natera
- Sequenom
- Silicon Biosystems
- Verinata Health
Note: Product cover images may vary from those shown
Adroll
adroll